Compare DexCom, Inc. (DXCM) vs General Dynamics Corporation (GD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs General Dynamics Corporation — how do they compare? DexCom, Inc. trades at $83.9 (market cap $31.86B), while General Dynamics Corporation trades at $331.24 (market cap $89.26B). The key difference: General Dynamics Corporation is far larger — about 2.8× DexCom, Inc.'s market cap, and General Dynamics Corporation pays a 1.93% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and General Dynamics Corporation for 85 Days on average.
| DXCM | GD | |
|---|---|---|
Market Cap | $31.86B | $89.26B |
Volume | 3,607,070 | 1,496,273 |
Sector | Health | Industrials |
52-Week High | $92.34 | $395.97 |
52-Week Low | $54.84 | $312.53 |
Typical Hold Time | 62 Days | 85 Days |
Enterprise Value | $31.32B | $94.40B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
General Dynamics (GD) trades at $331.77, up 1.57% today, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q3 2026 expected at $4.14. Revenue grew to $52.55B in 2025, and net income margin improved to 8.18%. Analyst consensus is bullish with a $420.57 price target, supported by defense budget tailwinds and dividend stability.
The outlook remains positive due to robust Pentagon spending and contract visibility, though technical weakness near support at $320 poses short-term risk. Long-term growth is underpinned by submarine and vehicle demand, but investors face volatility from defense budget cycles and geopolitical uncertainties. The stock offers value with a P/E of 20.12 and a sustainable dividend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
